Dragonfly Therapeutics announced a new research collaboration with Bristol Myers Squibb to discover and develop Dragonfly’s novel immunotherapies for multiple sclerosis and neuro-inflammation targets.
Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs. The two preclinical programs are for amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).
While COVID-19 has caused the delay in some clinical trials and hampered workflow in the biopharma industry due to social distancing concerns, some companies have pushed ahead with initial public offerings (IPO) in hopes of securing investor monies to support drug and business development.
Biopharmaceutical companies need to look beyond the usual targets when addressing neurodegenerative disorders and also must work to correlate genetic changes to cognitive changes in patients, according to panelists at BIO’s on-demand session, “Battle of the Brains: Rethinking Neurodegenerative Disease Treatment.”
Denali Therapeutics and development partner Sanofi announced data from the Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). After apparent disappointing results, the companies have chosen to pause the studies with the drug and shift their resources to a similar drug, DNL788, for the same indications.
Seattle-based Athira Pharma closed on a Series B financing worth $85 million, led by Perceptive Advisors.
Cambridge, Mass.-based QurAlis Corporation increased the company’s financial footing following a $42 million Series A financing round that will be used to support the continued development of therapeutic drugs for ALS and genetically related frontotemporal dementia (FTD).
A review of some recently published scientific studies, including researchers at the University of Maryland Baltimore County identifying a single nucleotide that controls two forms of the HIV virus’ RNA.
For some time, there has been speculation that glucose metabolism was associated with Alzheimer’s disease, with some researchers going so far as to call Alzheimer’s diabetes type 3. Researchers with the National Institutes of Health’s National Institute on Aging conducted the largest study so far on proteins related to Alzheimer’s and identified proteins and biological processes that regulate glucose metabolism that are associated with Alzheimer’s. The study was published in the journal Nature Medicine.
AlzeCure Pharma AB appointed Martin Jönsson as the company’s new CEO.